Argus raised the price target for the Laboratory Corporation of America Holdings (NYSE:LH) stock from “a Buy” to “a Hold”. The rating was released on September 19, 2022, according to finviz. The research report from Deutsche Bank has downgraded the stock from Buy to Hold, with a price target set at $294. The stock was upgraded by Argus, who disclosed in a research note on January 11, 2021, from Hold to Buy and set the price objective to $245.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Laboratory Corporation of America Holdings (NYSE:LH) raised 0.65% to close Wednesday’s market session at $238.29, higher as compared to yesterday’s close. The stock price fluctuated between $236.49 and $239.09 throughout the trading session with the volume trading being 472503 shares, which represented a significant variation when compared to the three months average volume of 768.18K shares. The firm’s stock price fluctuated -2.26% within the last five trades and 4.42% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -3.68% in the last 6 months and 0.52% was added to its value over the previous 3 months. LH stock is trading at a margin of 2.41%, 7.92% and -2.55% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
As of the close of trading, LH deals in the Healthcare domain. The stock is trading -24.87 percent below its 52-week high and 18.95 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -15.3. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Laboratory Corporation of America Holdings’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 15.80 percent and the profit margin is 11.50 percent, and the company has reported a gross margin of 31.40 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $21.37 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Laboratory Corporation of America Holdings (NYSE:LH) is 12.72. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 13.51. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1.40 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 2.13, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.10 percent of Laboratory Corporation of America Holdings shares are owned by insiders, and 94.50 percent are held by financial institutions. Schroeder Mark S, the EVP, President-Diagnostics Lab at Laboratory Corporation of America Holdings (LH) has sold 1,116 shares of firm on Nov 08 at a price of $232.67 against the total amount of $0.26 million. In another inside trade, EISENBERG GLENN A, Chief Financial Officer, EVP of Laboratory Corporation of America Holdings (NYSE:LH) sold 25,000 shares of the firm on Sep 26 for a total worth of $5.27 million at a price of $210.62. An inside trade which took place on Sep 07, EVP, President of Diagnostics of Laboratory Corporation of America Holdings Caveney Brian J bought 44 shares of firm against total price of $10251.0 at the cost of $231.20 per share.